Sign inJoin waitlistJoin the waitlist

Philip Friedlander

Director of the Melanoma Medical Oncology Program · Mount Sinai

Credentials: · · · · · · ·

History

Icahn School of Medicine at Mount Sinai
Present
Mount Sinai
Present
Mount Sinai
Present

Memorial Sloan-Kettering Cancer Center
2003–2005
Internal Medicine
2000–2003
Columbia Presbyterian Medical Center
1999–2000
Columbia University
Columbia Univ Coll of Phys & Surgeons
1995–1999

Research

Efficacy and safety of vismodegib in advanced basal-cell carcinoma
New England Journal of Medicine · 2012 · 1,139 citations
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
New England Journal of Medicine · 2016 · 992 citations
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With…
Journal of Clinical Oncology · 2018 · 522 citations

Stephen Hodi
6 papers
Yvonne Saenger
5 papers
Adil Daud
4 papers
DF
David Fisher
4 papers
ES
Elad Sharon
4 papers
Frances Collichio
4 papers
Sara Perkins
4 papers
SO
Steven O'Day
4 papers
WO
William Oh
4 papers
AA
Annick Van den Abbeele
3 papers
Brent Hanks
3 papers · 2 as a resident
DL
Donald Lawrence
3 papers

Clinical trials

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Principal investigator · Recruiting · Phase 1
Nicholas Gulati
2022–2030
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Principal investigator · Recruiting
Icahn School of Medicine at Mount Sinai
2021–2028
Treatment With Nab-paclitaxel in Cutaneous SCC
Principal investigator · Terminated · Phase 2
Icahn School of Medicine at Mount Sinai
2014–2015
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Principal investigator · Terminated · Phase 1
Ludwig Institute for Cancer Research
2014–2016